Sign In
NASDAQ:IONS
Ionis Pharmaceuticals Stock News
$36.10
+0.370 (+1.04%)
At Close: Dec 02, 2024
Ionis Pharmaceuticals (IONS) Upgraded to Buy: What Does It Mean for the Stock?
01:01pm, Wednesday, 27'th Nov 2024
Ionis Pharmaceuticals (IONS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Here's Why Ionis Pharmaceuticals (IONS) is Poised for a Turnaround After Losing -13.46% in 4 Weeks
10:37am, Monday, 18'th Nov 2024
Ionis Pharmaceuticals (IONS) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnin
Ionis' Q3 Earnings and Revenues Beat Estimates, New Launches in Focus
04:01pm, Thursday, 07'th Nov 2024
IONS reports better-than-expected top and bottom-line numbers for the third quarter of 2024.
Ionis to present at upcoming investor conferences
07:05am, Thursday, 07'th Nov 2024
CARLSBAD, Calif. , Nov. 7, 2024 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will participate in fireside chats at the following investor conferences: Gug
Ionis Pharmaceuticals, Inc. (IONS) Q3 2024 Earnings Call Transcript
02:35pm, Wednesday, 06'th Nov 2024
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS ) Q3 2024 Earnings Conference Call November 6, 2024 11:30 AM ET Company Participants Wade Walke – Senior Vice President of Investor Relations Brett Monia –
Compared to Estimates, Ionis Pharmaceuticals (IONS) Q3 Earnings: A Look at Key Metrics
10:35am, Wednesday, 06'th Nov 2024
The headline numbers for Ionis Pharmaceuticals (IONS) give insight into how the company performed in the quarter ended September 2024, but it may be worthwhile to compare some of its key metrics to Wa
Ionis Pharmaceuticals (IONS) Reports Q3 Loss, Tops Revenue Estimates
09:10am, Wednesday, 06'th Nov 2024
Ionis Pharmaceuticals (IONS) came out with a quarterly loss of $0.95 per share versus the Zacks Consensus Estimate of a loss of $1.16. This compares to loss of $1.03 per share a year ago.
Ionis Announces Pivotal Phase 3 Trial Design for ION582 in Angelman Syndrome
07:01am, Wednesday, 06'th Nov 2024
Positive End of Phase 2 discussion with FDA, including alignment on Phase 3 design Bayley-4 expressive communication selected as Phase 3 study primary endpoint Initiation of ION582 Phase 3 study plann
Ionis reports third quarter 2024 financial results
07:00am, Wednesday, 06'th Nov 2024
WAINUA TM U.S. launch progressing well; approved in UK; positive CHMP opinion Olezarsen FCS PDUFA December 19, 2024 Donidalorsen HAE PDUFA August 21, 2025; EU regulatory submission in process On tra
Countdown to Ionis Pharmaceuticals (IONS) Q3 Earnings: A Look at Estimates Beyond Revenue and EPS
10:22am, Monday, 04'th Nov 2024
Besides Wall Street's top -and-bottom-line estimates for Ionis Pharmaceuticals (IONS), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared
Ionis announces FDA acceptance of New Drug Application for donidalorsen for prophylactic treatment of HAE
09:44am, Monday, 04'th Nov 2024
Donidalorsen will be a first-in-class RNA-targeted medicine for hereditary angioedema, assuming approval Donidalorsen PDUFA date set for August 21, 2025 Donidalorsen has the potential to be Ionis' sec
Ionis Pharmaceuticals (IONS) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
11:06am, Wednesday, 30'th Oct 2024
Ionis Pharmaceuticals (IONS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Ionis Pharmaceuticals: Catalysts Due In 2025/2026 Are Extremely Compelling
04:25pm, Wednesday, 23'rd Oct 2024
Ionis is a promising biotech with a strong late-stage pipeline and lucrative Big Pharma partnerships, despite current weak commercial revenues and heavy losses. The company has five FDA-approved drugs
Ionis to hold third quarter 2024 financial results webcast
07:05am, Wednesday, 23'rd Oct 2024
Webcast scheduled for Wednesday, November 6 at 11:30 a.m. Eastern Time CARLSBAD, Calif.
AstraZenca drug for nerve damage given EU Green light
02:59am, Monday, 21'st Oct 2024
AstraZeneca PLC (LSE:AZN) and Ionis Pharmaceuticals' (NASDAQ:IONS) drug Wainzua (eplontersen) has been recommended for approval in the European Union for treating hereditary transthyretin-mediated am
